- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.07. | ME Therapeutics Holdings Inc: ME Therapeutics investor Dhanji acquires shares | 1 | Stockwatch | ||
| 21.05. | ME Therapeutics Holdings Inc: ME Therapeutics to receive funding from NRC IRAP | 4 | Stockwatch | ||
| 03.03. | ME Therapeutics Holdings Inc.: ME Therapeutics Announces It Has Engaged Lucosky Brookman LLP to Explore a Listing on the NASDAQ or NYSE | 733 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - March 3, 2025) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company... ► Artikel lesen | |
| 14.01. | ME Therapeutics Holdings Inc.: ME Therapeutics Announces That Its First Therapeutic mRNA Candidate Shows Encouraging Anti-Cancer Efficacy in Vivo | 915 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - January 14, 2025) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company... ► Artikel lesen | |
| 25.10.24 | ME Therapeutics Holdings Inc. Appoints Chief Business Officer | 693 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - October 25, 2024) - ME Therapeutics Holdings Inc. (CSE:METX) (FSE:Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company... ► Artikel lesen | |
| ME THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 22.10.24 | ME Therapeutics Holdings Inc. Provides Research and Development Update and Corporate Update | 629 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - October 22, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company... ► Artikel lesen | |
| 18.09.24 | ME Therapeutics Holdings Inc.: ME Therapeutics Announces the Start of Testing of First mRNA Formulations from NanoVation Therapeutics Collaboration | 741 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - September 18, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company... ► Artikel lesen |
7 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SUMMIT THERAPEUTICS | 18,940 | 0,00 % | Summit Therapeutics rises as co-CEOs buy nearly $12M worth of company stock | ||
| AVIDITY BIOSCIENCES | 44,710 | +8,94 % | Avidity Biosciences (RNA) Gets 9% Boost from Higher PT, Rating | ||
| ARCELLX | 76,19 | -1,92 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| ADMA BIOLOGICS | 16,110 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| BIONTECH | 84,45 | +2,43 % | BioNTech SE: Erste Zwischenergebnisse aus BioNTechs und BMS' globaler Phase-2-Studie mit bispezifischem PD-L1xVEGF-A-Antikörperkandidat Pumitamig (BNT327/BMS986545) zeigen ermutigende Anti-Tumor-Aktivität bei fortgeschrittenem kleinzelligem Lungenkrebs | Daten zur Kombination des bispezifischen PD-L1xVEGF-A-Antikörper-Kandidaten Pumitamig (BNT327/BMS986545) mit Chemotherapie zeigen weiterhin ermutigende Anti-Tumor-Aktivitäten bei Patientinnen und Patienten... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,830 | 0,00 % | What Analysts Are Saying About Recursion Pharmaceuticals Stock | ||
| TOURMALINE BIO | 47,600 | 0,00 % | Novartis will Tourmaline Bio für 1,4 Milliarden Dollar übernehmen | DJ Novartis will Tourmaline Bio für 1,4 Milliarden Dollar übernehmen
Von Adam Whittaker
DOW JONES--Novartis will das US-Biopharmaunternehmen Tourmaline Bio für rund 1,4 Milliarden US-Dollar... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 37,060 | -0,27 % | Hedge Fund and Insider Trading News: Louis Bacon, Bill Ackman, Warren Buffett, Dan Loeb, Silver Point Capital, Starboard Value, Elliott Management, Mineralys Therapeutics Inc (MLYS), DuPont de Nemours Inc (DD), and More | ||
| RAPPORT THERAPEUTICS | 23,750 | 0,00 % | Rapport Therapeutics, Inc.: Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures | Trial met primary long episode endpoints with high statistical significance, and RAP-219 was generally well toleratedPatients achieved 77.8% reduction in clinical seizures (p=0.01), with 24% achieving... ► Artikel lesen | |
| TREVI THERAPEUTICS | 8,250 | -15,38 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates | Announced positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF
Closed $115 million underwritten... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 49,380 | -4,80 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements | Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded... ► Artikel lesen | |
| MAZE THERAPEUTICS | 23,270 | 0,00 % | Maze Therapeutics, Inc.: Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria ... | Phase 1 data in healthy volunteers exceed expectations and support best-in-class potential, enabling Phase 2 advancement for both intended indications of PKU and CKD Dose-dependent urinary amino acid... ► Artikel lesen | |
| TANGO THERAPEUTICS | 6,530 | -4,39 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights | - First patient dosed in combination trial of TNG462 and Revolution Medicines RAS(ON) inhibitors - - First patient dosed in Phase 1/2 trial with TNG456, a brain-penetrant MTA-cooperative PRMT5... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 19,960 | +0,20 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update | Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 47% with 32% of patients achieving MMR by 24 weeks... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 52,55 | -3,22 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update | Phase 3 VELA program in hidradenitis suppurativa (HS) on track for an expected primary endpoint readout around September 2025 and an expected submission of a Biologic License Application (BLA) in the... ► Artikel lesen |
Das Unternehmen ME THERAPEUTICS HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 2,840 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ME THERAPEUTICS HOLDINGS INC finden Sie auf Wallstreet Online.